Kristi Rosa
@kristirosa.bsky.social
Associate Editorial Director of OncLive. Bookworm. Writer. Foodie. Cat lady.
📣 JUST RELEASED 📣: The latest installment of #OncologyUnplugged! 🔌 🎙️ In this episode, Dr Chandler Park and Dr Joshua Brody @mountsinainyc.bsky.social, explore the heterogeneity of lymphoma subtypes & the evolution of treatment paradigms across B-cell malignancies. 🎧: www.onclive.com/view/clinica...
January 9, 2025 at 2:12 AM
📣 JUST RELEASED 📣: The latest installment of #OncologyUnplugged! 🔌 🎙️ In this episode, Dr Chandler Park and Dr Joshua Brody @mountsinainyc.bsky.social, explore the heterogeneity of lymphoma subtypes & the evolution of treatment paradigms across B-cell malignancies. 🎧: www.onclive.com/view/clinica...
Reposted by Kristi Rosa
In this episode of #OncLiveOnAir 🎙️🎧, Onyee Chan, MD, of
@moffittnews.bsky.social, and Bradley D. Hunter, MD, of
Intermountain Healthcare, discuss evolving treatment strategies in chronic myeloid leukemia. Listen now: onclive.com/view/ascimin... #leusm #medtwitter #oncology
@moffittnews.bsky.social, and Bradley D. Hunter, MD, of
Intermountain Healthcare, discuss evolving treatment strategies in chronic myeloid leukemia. Listen now: onclive.com/view/ascimin... #leusm #medtwitter #oncology
December 31, 2024 at 1:24 AM
In this episode of #OncLiveOnAir 🎙️🎧, Onyee Chan, MD, of
@moffittnews.bsky.social, and Bradley D. Hunter, MD, of
Intermountain Healthcare, discuss evolving treatment strategies in chronic myeloid leukemia. Listen now: onclive.com/view/ascimin... #leusm #medtwitter #oncology
@moffittnews.bsky.social, and Bradley D. Hunter, MD, of
Intermountain Healthcare, discuss evolving treatment strategies in chronic myeloid leukemia. Listen now: onclive.com/view/ascimin... #leusm #medtwitter #oncology
Reposted by Kristi Rosa
Reposted by Kristi Rosa
What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors in #breastcancer? 💊
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
Concomitant intake of proton pump inhibitors (PPIs) may create drug–drug interactions, potentially impacting efficacy of anticancer agents. In the pha…
www.sciencedirect.com
January 3, 2025 at 6:46 PM
What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors in #breastcancer? 💊
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Reposted by Kristi Rosa
MECCA trial:
💊💊💊Despite past views of endocrine therapy as antagonistic, Metronomic capecitabine + AI significantly improves PFS (20.9 vs. 11.9 mo) & OS in HR+/HER2- MBC. @oncoalert.bsky.social @oncbrothers.bsky.social @ptarantinomd.bsky.social @tmprowell.bsky.social
doi.org/10.1200/JCO.24…
💊💊💊Despite past views of endocrine therapy as antagonistic, Metronomic capecitabine + AI significantly improves PFS (20.9 vs. 11.9 mo) & OS in HR+/HER2- MBC. @oncoalert.bsky.social @oncbrothers.bsky.social @ptarantinomd.bsky.social @tmprowell.bsky.social
doi.org/10.1200/JCO.24…
January 4, 2025 at 4:20 PM
MECCA trial:
💊💊💊Despite past views of endocrine therapy as antagonistic, Metronomic capecitabine + AI significantly improves PFS (20.9 vs. 11.9 mo) & OS in HR+/HER2- MBC. @oncoalert.bsky.social @oncbrothers.bsky.social @ptarantinomd.bsky.social @tmprowell.bsky.social
doi.org/10.1200/JCO.24…
💊💊💊Despite past views of endocrine therapy as antagonistic, Metronomic capecitabine + AI significantly improves PFS (20.9 vs. 11.9 mo) & OS in HR+/HER2- MBC. @oncoalert.bsky.social @oncbrothers.bsky.social @ptarantinomd.bsky.social @tmprowell.bsky.social
doi.org/10.1200/JCO.24…
Reposted by Kristi Rosa
www.nature.com/articles/d41...
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
2024 FDA approvals
The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine and much more.
www.nature.com
January 4, 2025 at 5:43 PM
www.nature.com/articles/d41...
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
Excited to announce the launch of #FDAReport: The Regulatory Rundown ✅ 🔍. Each month, @onclive.bsky.social will provide you with a monthly snapshot of all therapeutic options approved by the @fda.gov spanning tumor types. The December edition is now LIVE! ✨: www.onclive.com/view/onclive...
January 4, 2025 at 8:54 PM
Excited to announce the launch of #FDAReport: The Regulatory Rundown ✅ 🔍. Each month, @onclive.bsky.social will provide you with a monthly snapshot of all therapeutic options approved by the @fda.gov spanning tumor types. The December edition is now LIVE! ✨: www.onclive.com/view/onclive...
Reposted by Kristi Rosa
US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL @ash-hematology.bsky.social #ASH24 #lymsm #hematology www.onclive.com/view/us-real...
US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL
Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.
www.onclive.com
December 8, 2024 at 9:24 PM
US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL @ash-hematology.bsky.social #ASH24 #lymsm #hematology www.onclive.com/view/us-real...
Reposted by Kristi Rosa
🚨 ATTN 🚨: We are LIVE in sunny San Diego☀️, covering the 66th Annual @ash-hematology.bsky.social Annual Meeting. #ASH24 #oncology
Check back on our website to stay up to date on the latest updates and expert insights throughout the conference 👉: onclive.com/conference/ash
Check back on our website to stay up to date on the latest updates and expert insights throughout the conference 👉: onclive.com/conference/ash
December 7, 2024 at 8:45 PM
🚨 ATTN 🚨: We are LIVE in sunny San Diego☀️, covering the 66th Annual @ash-hematology.bsky.social Annual Meeting. #ASH24 #oncology
Check back on our website to stay up to date on the latest updates and expert insights throughout the conference 👉: onclive.com/conference/ash
Check back on our website to stay up to date on the latest updates and expert insights throughout the conference 👉: onclive.com/conference/ash